NASDAQ:GYRE Gyre Therapeutics (GYRE) Stock Price, News & Analysis $7.20 +0.18 (+2.56%) Closing price 08/7/2025 04:00 PM EasternExtended Trading$7.35 +0.15 (+2.08%) As of 08/7/2025 06:05 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Gyre Therapeutics Stock (NASDAQ:GYRE) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Gyre Therapeutics alerts:Sign Up Key Stats Today's Range$7.02▼$7.4750-Day Range$6.65▼$9.1052-Week Range$6.11▼$19.00Volume103,870 shsAverage Volume76,865 shsMarket Capitalization$675.07 millionP/E Ratio360.18Dividend YieldN/APrice TargetN/AConsensus RatingBuy Company Overview Gyre Therapeutics, Inc., a biopharmaceutical company, primarily focuses on the development and commercialization of Hydronidone for the treatment of Metabolic Dysfunction Associated Steatohepatitis in the United States. Its Hydronidone is also being evaluated for the treatment of liver fibrosis across a spectrum of chronic liver diseases. In addition, it advances a product pipeline in China, including Pirfenidone, for dermatomyositis interstitial lung disease, systemic sclerosis-associated interstitial lung disease, and pneumoconiosis, as well as for diabetic kidney disease; and product candidates for acute-on-chronic liver failure, chronic obstructive pulmonary disease, and pulmonary arterial hypertension. The company was founded in 2002 and is headquartered in San Diego, California. Read More Gyre Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks0th Percentile Overall ScoreGYRE MarketRank™: Gyre Therapeutics scored higher than 0% of companies evaluated by MarketBeat, and ranked 921st out of 921 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's OpinionN/AAnalyst RatingN/A Consensus RatingThere is not enough analysis data for Gyre Therapeutics.Read more about Gyre Therapeutics' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of Gyre Therapeutics is 360.18, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 27.80.Price to Earnings Ratio vs. SectorThe P/E ratio of Gyre Therapeutics is 360.18, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 29.88.Price to Book Value per Share RatioGyre Therapeutics has a P/B Ratio of 6.86. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Gyre Therapeutics' valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted11.13% of the float of Gyre Therapeutics has been sold short.Short Interest Ratio / Days to CoverGyre Therapeutics has a short interest ratio ("days to cover") of 8.3.Change versus previous monthShort interest in Gyre Therapeutics has recently increased by 0.56%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldGyre Therapeutics does not currently pay a dividend.Dividend GrowthGyre Therapeutics does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted11.13% of the float of Gyre Therapeutics has been sold short.Short Interest Ratio / Days to CoverGyre Therapeutics has a short interest ratio ("days to cover") of 8.3.Change versus previous monthShort interest in Gyre Therapeutics has recently increased by 0.56%, indicating that investor sentiment is decreasing. News and Social Media0.0 / 5News SentimentN/A News Coverage This WeekMarketBeat has tracked 1 news article for Gyre Therapeutics this week, compared to 2 articles on an average week. Company Ownership0.8 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Gyre Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $23,804.00 in company stock.Percentage Held by InsidersOnly 10.00% of the stock of Gyre Therapeutics is held by insiders.Percentage Held by InstitutionsOnly 23.99% of the stock of Gyre Therapeutics is held by institutions.Read more about Gyre Therapeutics' insider trading history. Receive GYRE Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Gyre Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address GYRE Stock News HeadlinesGyre Therapeutics: Unique Business Model, Unique ChallengesJune 30, 2025 | seekingalpha.comGYRE - Gyre Therapeutics Inc Sustainability - MorningstarJune 26, 2025 | morningstar.comMTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger the biggest forced rotation of capital since World War II. They reveal why Trump is mobilizing America’s tech giants… and name the two stocks most likely to soar as trillions shift behind the scenes. | Porter & Company (Ad)Gyre Therapeutics, Inc. (GYRE) Latest Press Releases & Corporate News - Yahoo FinanceJune 24, 2025 | ca.finance.yahoo.comPublic companies account for 71% of Gyre Therapeutics, Inc.'s (NASDAQ:GYRE) ownership, while individual investors account for 19%June 20, 2025 | finance.yahoo.comGNI Group’s Gyre Therapeutics Begins Phase 1 Trial for PAH Drug in ChinaJune 11, 2025 | msn.comGyre Therapeutics Inc.: Gyre Therapeutics Announces First Dosing in Phase 1 Trial of F230 for Pulmonary Arterial Hypertension in ChinaJune 10, 2025 | finanznachrichten.deGyre Therapeutics Announces First Dosing in Phase 1 Trial of F230 for Pulmonary Arterial Hypertension in ChinaJune 10, 2025 | globenewswire.comSee More Headlines GYRE Stock Analysis - Frequently Asked Questions How have GYRE shares performed this year? Gyre Therapeutics' stock was trading at $12.10 at the beginning of 2025. Since then, GYRE stock has decreased by 40.5% and is now trading at $7.20. How were Gyre Therapeutics' earnings last quarter? Gyre Therapeutics, Inc. (NASDAQ:GYRE) posted its quarterly earnings results on Friday, May, 9th. The company reported $0.03 EPS for the quarter, hitting the consensus estimate of $0.03. The firm earned $22.06 million during the quarter, compared to analyst estimates of $28.40 million. Gyre Therapeutics had a net margin of 7.20% and a trailing twelve-month return on equity of 9.73%. How do I buy shares of Gyre Therapeutics? Shares of GYRE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Gyre Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Gyre Therapeutics investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Netflix (NFLX), Broadcom (AVGO), Palo Alto Networks (PANW) and Invesco QQQ (QQQ). Company Calendar Last Earnings5/09/2025Today8/07/2025Next Earnings (Estimated)8/12/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:GYRE Previous SymbolNASDAQ:GYRE CIK1124105 Webwww.catalystbiosciences.com Phone(619) 949-3681Fax336-480-2107Employees40Year FoundedN/AProfitability EPS (Trailing Twelve Months)$0.02 Trailing P/E Ratio360.18 Forward P/E RatioN/A P/E GrowthN/ANet Income$12.09 million Net Margins7.20% Pretax Margin15.27% Return on Equity9.73% Return on Assets7.66% Debt Debt-to-Equity RatioN/A Current Ratio3.60 Quick Ratio3.19 Sales & Book Value Annual Sales$105.76 million Price / Sales6.38 Cash Flow$0.21 per share Price / Cash Flow35.04 Book Value$1.05 per share Price / Book6.86Miscellaneous Outstanding Shares93,760,000Free Float84,382,000Market Cap$675.07 million OptionableNo Data Beta1.80 Elon Musk's Next MoveExplore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.Get This Free Report This page (NASDAQ:GYRE) was last updated on 8/8/2025 by MarketBeat.com Staff From Our PartnersBREAKING: The House just passed 3 pro-crypto bills!THREE pro-crypto bills just passed the House! Now, experts believe altcoin season is officially here. Crypto 101 Media | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredProtect Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredAmazon’s big Bitcoin embarrassmentBitcoin just passed Amazon in total market cap — but most investors are missing the bigger opportunity. Whi...Brownstone Research | SponsoredAltucher: Trump’s Great Gain is startingNew Hampshire just launched a Strategic Crypto Reserve — and James Altucher says it’s the first sign that “Tru...Paradigm Press | SponsoredCritical AI announcement set to ignite AI 2.0 A new 100% tariff on imported chips just rattled the tech sector—sending some stocks soaring and others tumbli...Timothy Sykes | SponsoredTrump’s new nightmareAccording to Porter Stansberry and Jeff Brown, a government-led financial mobilization is already reshaping Am...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Gyre Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Gyre Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.